



No boundaries in
Infection Research
and Care



Oral Communications

ID	N.pgm	Title	Presenting Author
22/05/2025 11.10 - 12.10 The statins breakthrough in HIV management			
37	OC 1	Achievement of Low-Density Lipoprotein (LDL-C) Targets Based on Individual Cardiovascular Risk in a Cohort of People with HIV (PWH): One-Year Follow-Up Assessment	Beatrice Caloni, Milano
244	OC 2	Statin prescription, acceptability and tolerability in a cohort of people living with HIV (PLWH) after updated recommendations on statin therapy	Alessandra Bailoni, Siena
176	OC 3	Impact of REPRIEVE indications on statin prescription in people with HIV in a real-life setting	Rebecka Papaioannu Borjesson, Milano
338	OC 4	Statins reduce frailty in people with HIV	Jovana Milic, Modena
22/05/2025 12.15 - 13.15 The evolving tale of HIV: shifting patterns, emerging HIV care			
255	OC 5	Progresses in the continuum of care of people living with HIV, using surveillance and cohort data. Italy, 2012-2023	Assunta Navarra, Roma
260	OC 6	Disaggregated data on testing activity for HIV in the context of community based voluntary counselling and testing services in the last years in Italy (2019-2023): towards a national registry	Pierluca Piselli, Roma
5	OC 7	Expanding HIV Screening Beyond Hospital Walls in Milan: 17 years of the "EasyTest" project	Angelo Roberto Raccagni, Milano
261	OC 8	Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?	Annalisa Mondì, Roma
22/05/2025 14.05 - 15.05 Long acting PrEP in clinical practice			
167	OC 9	Preliminary insights into the pharmacokinetics of long-acting Cabotegravir for PrEP: differential blood and seminal fluid concentrations analysis	Eleonora Sabetta, Milano
209	OC 10	Preliminary Results of Long-Acting Injectable PrEP with Cabotegravir at San Raffaele Institute in Milan	Angelo Roberto Raccagni, Milano
78	OC 11	Determinants for the start of long-acting injectable cabotegravir as pre-exposure prophylaxis: a case-control analysis	Gabriele Cavazza, Milano
292	OC 12	Real-world implementation of long-acting PrEP with injectable cabotegravir: preliminary data from an Italian cohort	Valentina Mazzotta, Roma
22/05/2025 14.30 - 15.55 Defining immune correlates in the context of ART and vaccination			
262	OC 13	The impact of long-acting injectable cabotegravir plus rilpivirine in PWH on macrophage/monocyte activation and neuronal injury	Maria Antonella Zingaropoli, Roma
221	OC 14	Changes in CD8+ T-cell activation after switching from suppressive 3-drug to 2-drug cART in people with HIV	Diego Ripamonti, Bergamo
150	OC 15	Impact of long-acting therapy and CMV-coinfection on immune activation and senescence in People with HIV(PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine	Mariasilvia Guardiani, Roma
7	OC 16	Long-lasting immunity: smallpox-specific T Cells show distinct memory traits compared to SARS-CoV-2 T Cells	Sara De Biasi, Modena
95	OC 17	Two-year neutralizing and T-cell response after MVA-BN vaccination according to HIV infection and CD4 cell count	Valentina Mazzotta, Roma
31	OC 18	Assessment of the specific cellular immune response to the recombinant herpes zoster vaccine in people living with HIV	Grazia Alessio, Roma



*No boundaries in
Infection Research
and Care*



Oral Communications

ID	N.pgm	Title	Presenting Author
22/05/2025 15.10 - 16.10 Optimizing HIV infection management in Italian clinical practice			
132	OC 19	Effectiveness of switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from NNRTI-based ART in virologically suppressed HIV-patients: a retrospective analysis (DRIVE-SWITCH Study)	Roberta Gagliardini, Roma
335	OC 20	Switching to BICTegavir in ELderly people living with HIV-1 under virologic control: week 144 results from the BICTEL cohort	Riccardo Donà, Roma
116	OC 21	Effectiveness and safety of switching to BIC/FTC/TAF in second, third and later lines of therapy in virologically suppressed people living with HIV (PWH) on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL STUDY)	Maria Vittoria Cossu, Milano
22/05/2025 16.15 - 17.30 From virus variability to disease and treatment			
59	OC 22	Evaluation of genetic variability and resistance profile in highly treatment-experienced people with HIV-1 with multi-drug resistance enrolled in the PRESTIGIO Registry treated with lenacapavir	Daniele Spalletta, Roma
60	OC 23	Evaluation of the viral reservoir in virologically suppressed people with HIV treated with LA Cabotegravir + Rilpivirine regimen	Greta Marchegiani, Roma
157	OC 24	An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity	Lorenzo Piermatteo, Roma
46	OC 25	Evaluation of the SARS-CoV-2 virus genetic barrier to Remdesivir and Nirmatrelvir in vitro and in vivo	Ilenia Varasi, Siena
110	OC 26	Whole Genome Sequencing of Adenovirus genotypes and clinical implications in pediatric patients	Luna Colagrossi, Roma
22/05/2025 16.15 - 17.30 Beyond viral suppression: rethinking quality of life in HIV care			
128	OC 27	Stigma experienced by person with HIV/AIDS in the healthcare settings	Lolita Sasset, Padova
316	OC 28	Challenges in Measuring Health-Related Quality of Life Among Antiretroviral Therapy Experienced People with HIV	Marianna Menozzi, Modena
85	OC 29	Poor Treatment Satisfaction and Low Quality of Life in Highly-Treatment Experienced People with HIV PWH: insights from PRESTIGIO Registry	Maria Mazzitelli, Padova
72	OC 30	Neurocognitive Impairment, Sleep Quality, Depression and Anxiety in People Living with HIV: A Cross-Sectional Study	Ambra Barco, Novara
232	OC 31	Adherence to electronic monitoring of PROs according with multidimensional biophenotypes (MBP)	Elena Matteini, Roma
23/05/2025 10.05 - 11.05 Durability of long-acting ART			
286	OC 32	Effectiveness and Safety of Long-Acting Cabotegravir and Rilpivirine in Older People with HIV: Insights from the GEPPCO Cohort	Emanuele Foca', Brescia
273	OC 33	Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCohoLART Study	Gabriele Loi, Milano
84	OC 34	Durability of long acting cabotegravir and rilpivirine in a multicenter real-life cohort of people with HIV	Maria Mazzitelli, Padova
199	OC 35	Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study	Camilla Muccini, Milano



Oral Communications

ID	N.pgm	Title	Presenting Author
23/05/2025 11.10 - 12.10 Building connections across care, prevention and education			
51	OC 36	Anlaids School - Through a positive and inclusive view of Sexuality, our STI prevention training	Silvia Negri, Roma
229	OC 37	Proactive testing for sexually transmitted and endemic diseases at an open access clinic for migrants: a one year update	Riccardo Ligresti, Milano
68	OC 38	NGO role in Continuum of Care (CoC): An opportunity not to be missed	Antonella Camposeragna, Roma
52	OC 39	Chemsex and MDPV: the experience of a community-based chemsex service with increasingly severe and complex clients	Alessandra Maria Bianchi, Milano
23/05/2025 12.15 - 13.15 Clinical HIV insights			
47	OC 40	Incidence of non-AIDS-related cancers in people with HIV in the period 2000 -2023: a single center retrospective study	Giacomo Pozza, Milano
108	OC 41	Treatment interruptions among PWH on INSTI: virologic failure and other reasons for switching therapy in a real-life cohort	Nicola Squillace, Monza
280	OC 42	Key predictors of optimal viro-immunological response in primary HIV infection	Annalisa Mondì, Roma
247	OC 43	Body composition and pharmacokinetics of long-acting antiretroviral therapies in a cohort of people living with HIV	Stefania Arsuffi, Brescia
23/05/2025 12.15 - 13.15 The long-acting ART landscape in Italy			
186	OC 44	Virologic outcomes of long acting cabotegravir and rilpivirine in viraemic and poorly adherent PLWH	Gabriele Cavazza, Milano
279	OC 45	Switching to Long-Acting CAB/RPV: A Real-World Analysis in People Living with HIV	Ludovica De Martino, Roma
133	OC 46	Effectiveness and patient reported outcomes (PROs) of long-acting ART with cabotegravir/rilpivirine: the Long-Icona study	Roberta Gagliardini, Roma
293	OC 47	Patient-reported outcomes (PROs) as a measure of satisfaction with Long-Acting therapy in PWH	Giulia Del Duca, Roma
23/05/2025 12.15 - 13.15 Advances in viral pathogenesis			
179	OC 48	HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential	Stefano D'Anna, Roma
54	OC 49	Plasma JCV-DNA changes as prognostic marker in Progressive Multifocal Leukoencephalopathy	Ilaria Mainardi, Milano
12	OC 50	Baseline viral load impacts the aging process in infants with perinatally acquired HIV enrolled in the EARTH cohort	Maria Raffaella Petrara, Padova
134	OC 51	Expression of HCMV-encoded miRNAs in co-infected PLWH and relationships with inflammation/immune activation	Elisabetta Lazzari, Roma
23/05/2025 14.00 - 15.00 Long-term effectiveness of oral ART			
207	OC 52	Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study	Antonella d'Arminio Monforte, Milano
65	OC 53	Observational effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced people with HIV across age groups: 24-month results from the Italian BICSTaR cohort	Diana Canetti, Milano
105	OC 54	Ten years results on the effectiveness and safety of DTG+3TC as a switch regimen in the ODOACRE cohort	Gianmaria Baldin, Roma
202	OC 55	Long-term durability of dolutegravir/lamivudine dual regimen in a real-world setting (Dolu3TC study)	Diego Ripamonti, Bergamo

Oral Communications

ID	N.pgm	Title	Presenting Author
23/05/2025 14.00 - 15.00 Access to prevention in different settings			
114	OC 56	Rising chemsex trends among PrEP users in Milan: a 2024-2025 study	Chiara Fusetti, Milano
36	OC 57	TelePrEP: New data on a best practice in HIV prevention	Maria Luisa Cosmaro, Milano
32	OC 58	Is PrEP knowledge a privilege? The unequal access to PrEP Information for cis and trans women and gender non-conforming individuals at HIV testing sites	Carlotta Del Giudice, Torino
63	OC 59	Facilitators and Barriers HIV/STI Information and Services Among LGBTQI+ Immigrants in Italy	Yerina Ranjit, Columbia
23/05/2025 14.00 - 15.00 HIV and comorbidities			
126	OC 60	Long-Term Success of Combined Kidney-Liver Transplantation in People with HIV: Evidence from a Real-World Cohort	Adriana Cervo, Modena
123	OC 61	HIV-to-HIV Organ Transplantation: A Comparative Analysis of Liver and Kidney Transplant Outcomes in People with HIV Receiving Organs from donors without HIV infection	Adriana Cervo, Modena
161	OC 62	Tobacco and Alternative Nicotine Product Use Among People With HIV: Should We Be Concerned?	Andrea De Vito, Sassari
230	OC 63	Hypertriglyceridemia and Gender Differences in the Risk of Major Adverse Cardiovascular Events in People with HIV: A Single Center Retrospective Longitudinal Study	Alessia Siribelli, Milano
23/05/2025 14.00 - 15.00 Diagnosis, prevalence and prevention of STIs			
183	OC 64	Clinical evaluation of gonococcal-specific culture test for rectal gonorrhea diagnosis	Flavia Passini, Milano
154	OC 65	Progressive Increase of New Syphilis Diagnoses among MSM with HIV Infection: A 30-Year Report from Rome STI Reference Center	Christof Stingone, Roma
79	OC 66	High-Risk HPV Other than HPV16 Are Common in Advanced Anal Precancerous Lesions in MSM Living With HIV	Eugenio Nelson Cavallari, Roma
73	OC 67	The actual need of doxyPEP might not be as large as expected	Roberto Rossotti, Milano
23/05/2025 15.05 - 16.05 ARV drugs from prevention to treatment			
312	OC 68	The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry	Tommaso Clemente, Milano
165	OC 69	Risk of developing low-level viral rebound (LLVR) among people with HIV (PWH) with current HIV-RNA ≤50 copies/mL receiving 2DR vs 3DR: a case control study	Adriana Cervo, Modena
282	OC 70	Advancing HIV care in pregnancy: trends in virological suppression, mother-to-child transmission and postpartum retention over two decades	Federica Casari, Modena
159	OC 71	Predictors of linkage to prevention services after HIV Post-Exposure Prophylaxis (PEP): a retrospective analysis from 2019 to 2024	Rozenn Esvan, Roma
23/05/2025 15.05 - 16.05 PrEP issues: adherence and STI			
343	OC 72	Comparison of users accessing PrEP in hospital-based or community-based settings: first picture from the PrIDE cohort	Valentina Mazzotta, Roma
57	OC 73	Comparing Self-Reported and Pharmacy-Based Monitoring Adherence rates in individual accessing HIV Pre-Exposure Prophylaxis (PrEP): An 18-Month Retrospective Analysis	Roberto Brunoro, Padova
121	OC 74	STI occurrence among PrEP users: a six-year follow-up study from the Bergamo centre	Serena Venturelli, Bergamo
83	OC 75	PrEP and STIs screening policies: one size fits all?	Enrico Schlitzer, Bologna